Natera Q1 revenue jumps; raises FY guidance; MRD patents upheld
Natera reported Q1 2026 revenue of $696.6M, raised full-year guidance to $2.74B–$2.82B, and won a court ruling upholding three MRD patents tied to a 30% ongoing royalty and preserved damages vs. Invitae. The update also mentions Signatera stage 1 post-surgery positivity in NSCLC with an indicated ~5x outcome related me